Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.
Bay Area’s Principia Biopharma Eyes $86 Million IPO
Autoimmune Diseases, Biotech, Bruton's Tyrosine Kinase (BTK) Inhibitors, Business, Immune Thrombocytopenic Purpura (ITP), Immunological Diseases, IPO, Multiple Sclerosis, Pemphigus, Pemphigus Vulgaris (PV), U.S. Securities and Exchange Commission (SEC)South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering.